Chemical Property of Tazobactam
Chemical Property:
- Appearance/Colour:White or off-white powder
- Vapor Pressure:5.55E-21mmHg at 25°C
- Melting Point:115-145℃
- Refractive Index:1.817
- Boiling Point:707.1 °C at 760 mmHg
- PKA:2.33±0.40(Predicted)
- Flash Point:381.4 °C
- PSA：127.43000
- Density:1.92 g/cm3
- LogP:-0.40470
- Storage Temp.:Store at?0-5°C
- Solubility.:DMSO (Slightly, Heated), Methanol (Slightly, Heated, Sonicated)
- Water Solubility.:Soluble in water
- XLogP3:-2
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:3
- Exact Mass:300.05284067
- Heavy Atom Count:20
- Complexity:573
- Purity/Quality:
-
98%min *data from raw suppliers
Tazobactam *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xi
- Hazard Codes:Xi
- Statements:
36/37/38
- Safety Statements:
26-36
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
- Isomeric SMILES:C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
- Recent ClinicalTrials:Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Recent EU Clinical Trials:Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in hematologic patients (BEATLE study).
-
Description
Tazobactam often is coadministered with piperacillin because of tazobactam's ability to inhibit β-lactamases.
T azobactam, like other β-lactamase inhibitors, has little or no antibacterial activity. This effect is analogous
to that of clavulanic acid and sulbactam.
-
Uses
b-lactamase inhibitor Tazobactam is a β-Lactamase inhibitor, used with β-lactam antibiotics to enhance their effect.
-
Therapeutic Function
Antibiotic
-
Clinical Use
Tazobactam is a penicillanic acid sulfone that is similar instructure to sulbactam. It is a more potent β-lactamaseinhibitor than sulbactam and has a slightly broader spectrumof activity than clavulanic acid. It has very weak antibacterialactivity. Tazobactam is available in fixed-dose, injectablecombinations with piperacillin, a broad-spectrum penicillinconsisting of an 8:1 ratio of piperacillin sodium to tazobactamsodium by weight and marketed under the trade name Zosyn.The pharmacokinetics of the two drugs are very similar. Bothhave short half-lives (t1/2 ～1 hour), are minimally proteinbound, experience very little metabolism, and are excreted inactive forms in the urine in high concentrations.Approved indications for the piperacillin–tazobactamcombination include the treatment of appendicitis, postpartumendometritis, and pelvic inflammatory disease caused byβ-lactamase–producing E. coli and Bacteroides spp., skin andskin structure infections caused by β-lactamase–producingS. aureus, and pneumonia caused by β-lactamase–producingstrains of H. influenzae.
-
Drug interactions
Potentially hazardous interactions with other drugs
Reduced excretion of methotrexate - monitor
methotrexate levels during concomitant treatment.
Enhanced action of vecuronium and similar
neuromuscular blocking agents.
